ArticleThe American journal of pathology1996
Progressive loss of CD44 gene expression in invasive bladder cancer.
Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 107 citations in OpenAlex.
- Recent advances in bladder cancer stem cells (BCSCs): A descriptive review of emerging therapeutic targets.iScience · 2025Review
- The clinicopathological and prognostic value of CD44 expression in bladder cancer: a study based on meta-analysis and TCGA data.Bioengineered · 2020Article
- Article
- Significance of E-cadherin and CD44 expression in patients with unresectable metastatic colorectal cancer.Oncology letters · 2017Article
- Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.European journal of medical research · 2014Article
- Relationship of PCNA, C-erbB2 and CD44s expression with tumor grade and stage in urothelial carcinomas of the bladder.International journal of clinical and experimental medicine · 2014Article
- Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.Diagnostic pathology · 2013Article
- Clinical and biological implications of the tumor microenvironment.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2012Article
- Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells.Clinical & experimental metastasis · 2011Article
- Significance of CD44 expression in gastrointestinal stromal tumors in relation to disease progression and survival.World journal of surgery · 2007Article
- Expression of CD44s in human colorectal cancer.Pathology oncology research : POR · 2002Article
- CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors.International urology and nephrology · 2001Article
- The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.British journal of cancer · 2001Article
- Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.The American journal of pathology · 1999Article
- CD44 cell adhesion molecules.Molecular pathology : MP · 1999Review
- Expression of CD44 variants and its association with survival in pancreatic cancer.Japanese journal of cancer research : Gann · 1998Article
- Expression patterns of CD44 adhesion molecule in testicular germ cell tumors and normal testes.The American journal of pathology · 1998Article
- Up-regulation of CD44 variant exon expression in endometrial carcinomas: analysis of mRNA and protein isoforms, and relation to clinicopathological factors.Japanese journal of cancer research : Gann · 1998Article
- CD44 and the adhesion of neoplastic cells.Molecular pathology : MP · 1997Review
- Dysregulation of mRNA splicing in urothelial carcinoma: Clinical, diagnostic and therapeutic implications.Bladder cancer (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated CD44 gene expression at both the RNA and protein level in well differentiated superficial and in deeply invasive bladder carcinomas. Proteins were studied by immunohistochemistry using antibodies against standard (CD44s) and variant (CD44v) isoforms. mRNA was analyzed by reverse transcriptase polymerase chain reaction/Southern blotting and in situ hybridization. Immunostaining with antibodies against CD44s and CD44v2, -5 and -6 (exons 7, 10, and 11, respectively) showed that carcinoma cells in all papillary tumors expressed strong signals throughout the epithelium but especially in the basal layer, which abuts on the stroma. However, invasive tumors, which are believed to originate mainly from flat urothelial tumors or, less frequently, from papillary carcinomas, progressively lost CD44 proteins as they penetrated deeper and became less differentiated. This change was paralleled at the mRNA level, by the gradual loss of expression of CD44s and CD44v transcripts in deeply invasive tumors until they were virtually undetectable. Conversely, papillary tumors contained multiple higher molecular weight transcripts, suggesting that the loss of CD44 proteins in the more aggressive tumors is due to a disturbance in transcription. This concept was confirmed by in situ hybridization studies with a probe showing that substantial variant CD44 mRNA is located in the urothelium in papillary carcinomas but is absent from deeply invasive carcinomas. These results indicate that initially there is a striking increase in CD44 gene expression in early bladder carcinomas, relative to normal urothelium, but that this diminishes as the tumors acquire a more aggressive phenotype.
Indexed as
Identifiers
8780391PMC1865145W29820694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.